-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the CDE official website showed that the pregabalin capsules of Hunan Sailong Pharmaceutical
Co.
According to data from Minet.
com, in 2020, the total sales of pregabalin capsules in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will total nearly 600 million yuan, and Pfizer has the largest market share
.
At present, 10 companies have production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies reporting production in the review and approval process
.
Co.
According to data from Minet.
com, in 2020, the total sales of pregabalin capsules in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will total nearly 600 million yuan, and Pfizer has the largest market share
.
At present, 10 companies have production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies reporting production in the review and approval process
.
Pregabalin capsules are mainly used for the treatment of post-herpetic neuralgia and fibromyalgia
.
The product was developed by Pfizer and was approved for marketing in the UK in 2004
.
.
The product was developed by Pfizer and was approved for marketing in the UK in 2004
.
According to data from Minet.
com, the sales of pregabalin capsules in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacy terminals in Chinese cities have grown rapidly in recent years, with a total of nearly 60% in 2020.
Among them, the terminal of public medical institutions in China increased by more than 40% year-on-year, and the terminal of physical pharmacies in Chinese cities increased by more than 35% year-on-year
.
com, the sales of pregabalin capsules in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacy terminals in Chinese cities have grown rapidly in recent years, with a total of nearly 60% in 2020.
Among them, the terminal of public medical institutions in China increased by more than 40% year-on-year, and the terminal of physical pharmacies in Chinese cities increased by more than 35% year-on-year
.
Pregabalin Capsules Generic Type 4 Reports Under Review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Pregabalin capsules are the fourth batch of domestically harvested varieties, and 4 companies including Qilu Pharmaceutical (Hainan) and China Resources Double Crane Pharmaceutical won the bid
.
At present, 10 companies have the production approval for this product, of which 8 have reviewed it
.
.
At present, 10 companies have the production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies applying for pregabalin capsules that are under review and approval.
Among them, Shandong Danhong Pharmaceutical | Shandong Buchang Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute | Sichuan Kelun Pharmaceutical, Yabao Pharmaceutical Taiyuan Pharmaceutical, 13 companies, including Nanjing Hailing Pharmaceuticals of Yangtze River Pharmaceutical Group, reported production as 4 types of imitations, and they were deemed to have been reviewed after approval
.
Among them, Shandong Danhong Pharmaceutical | Shandong Buchang Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute | Sichuan Kelun Pharmaceutical, Yabao Pharmaceutical Taiyuan Pharmaceutical, 13 companies, including Nanjing Hailing Pharmaceuticals of Yangtze River Pharmaceutical Group, reported production as 4 types of imitations, and they were deemed to have been reviewed after approval
.
Source: CDE official website, Minet database
A few days ago, the CDE official website showed that the pregabalin capsules of Hunan Sailong Pharmaceutical
Co.
According to data from Minet.
com, in 2020, the total sales of pregabalin capsules in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will total nearly 600 million yuan, and Pfizer has the largest market share
.
At present, 10 companies have production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies reporting production in the review and approval process
.
Co.
According to data from Minet.
com, in 2020, the total sales of pregabalin capsules in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will total nearly 600 million yuan, and Pfizer has the largest market share
.
At present, 10 companies have production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies reporting production in the review and approval process
.
Pregabalin capsules are mainly used for the treatment of post-herpetic neuralgia and fibromyalgia
.
The product was developed by Pfizer and was approved for marketing in the UK in 2004
.
.
The product was developed by Pfizer and was approved for marketing in the UK in 2004
.
According to data from Minet.
com, the sales of pregabalin capsules in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacy terminals in Chinese cities have grown rapidly in recent years, with a total of nearly 60% in 2020.
Among them, the terminal of public medical institutions in China increased by more than 40% year-on-year, and the terminal of physical pharmacies in Chinese cities increased by more than 35% year-on-year
.
com, the sales of pregabalin capsules in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacy terminals in Chinese cities have grown rapidly in recent years, with a total of nearly 60% in 2020.
Among them, the terminal of public medical institutions in China increased by more than 40% year-on-year, and the terminal of physical pharmacies in Chinese cities increased by more than 35% year-on-year
.
Pregabalin Capsules Generic Type 4 Reports Under Review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Pregabalin capsules are the fourth batch of domestically harvested varieties, and 4 companies including Qilu Pharmaceutical (Hainan) and China Resources Double Crane Pharmaceutical won the bid
.
At present, 10 companies have the production approval for this product, of which 8 have reviewed it
.
.
At present, 10 companies have the production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies applying for pregabalin capsules that are under review and approval.
Among them, Shandong Danhong Pharmaceutical | Shandong Buchang Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute | Sichuan Kelun Pharmaceutical, Yabao Pharmaceutical Taiyuan Pharmaceutical, 13 companies, including Nanjing Hailing Pharmaceuticals of Yangtze River Pharmaceutical Group, reported production as 4 types of imitations, and they were deemed to have been reviewed after approval
.
Among them, Shandong Danhong Pharmaceutical | Shandong Buchang Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute | Sichuan Kelun Pharmaceutical, Yabao Pharmaceutical Taiyuan Pharmaceutical, 13 companies, including Nanjing Hailing Pharmaceuticals of Yangtze River Pharmaceutical Group, reported production as 4 types of imitations, and they were deemed to have been reviewed after approval
.
Source: CDE official website, Minet database
A few days ago, the CDE official website showed that the pregabalin capsules of Hunan Sailong Pharmaceutical
Co.
According to data from Minet.
com, in 2020, the total sales of pregabalin capsules in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will total nearly 600 million yuan, and Pfizer has the largest market share
.
At present, 10 companies have production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies reporting production in the review and approval process
.
Co.
According to data from Minet.
com, in 2020, the total sales of pregabalin capsules in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will total nearly 600 million yuan, and Pfizer has the largest market share
.
At present, 10 companies have production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies reporting production in the review and approval process
.
Pregabalin capsules are mainly used for the treatment of post-herpetic neuralgia and fibromyalgia
.
The product was developed by Pfizer and was approved for marketing in the UK in 2004
.
.
The product was developed by Pfizer and was approved for marketing in the UK in 2004
.
According to data from Minet.
com, the sales of pregabalin capsules in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacy terminals in Chinese cities have grown rapidly in recent years, with a total of nearly 60% in 2020.
Among them, the terminal of public medical institutions in China increased by more than 40% year-on-year, and the terminal of physical pharmacies in Chinese cities increased by more than 35% year-on-year
.
Hospital Hospital Hospital Pharmacy Pharmacy Pharmacycom, the sales of pregabalin capsules in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacy terminals in Chinese cities have grown rapidly in recent years, with a total of nearly 60% in 2020.
Among them, the terminal of public medical institutions in China increased by more than 40% year-on-year, and the terminal of physical pharmacies in Chinese cities increased by more than 35% year-on-year
.
Pregabalin Capsules Generic Type 4 Reports Under Review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Pregabalin capsules are the fourth batch of domestically harvested varieties, and 4 companies including Qilu Pharmaceutical (Hainan) and China Resources Double Crane Pharmaceutical won the bid
.
At present, 10 companies have the production approval for this product, of which 8 have reviewed it
.
enterprise enterprise enterprise.
At present, 10 companies have the production approval for this product, of which 8 have reviewed it
.
In addition, there are 15 companies applying for pregabalin capsules that are under review and approval.
Among them, Shandong Danhong Pharmaceutical | Shandong Buchang Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute | Sichuan Kelun Pharmaceutical, Yabao Pharmaceutical Taiyuan Pharmaceutical, 13 companies, including Nanjing Hailing Pharmaceuticals of Yangtze River Pharmaceutical Group, reported production as 4 types of imitations, and they were deemed to have been reviewed after approval
.
Among them, Shandong Danhong Pharmaceutical | Shandong Buchang Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute | Sichuan Kelun Pharmaceutical, Yabao Pharmaceutical Taiyuan Pharmaceutical, 13 companies, including Nanjing Hailing Pharmaceuticals of Yangtze River Pharmaceutical Group, reported production as 4 types of imitations, and they were deemed to have been reviewed after approval
.
Source: CDE official website, Minet database
Source: CDE official website, Minet database 
